Background: Rising cancer incidence and mortality have increased the use of central venous catheters (CVCs), including peripherally inserted central catheters (PICCs) and port-a-cath systems (PCSs), which play an important role in treatment administration. However, CVCs are associated with mechanical, infectious, and thrombotic complications. This study evaluates PCS-related complications and their management in oncological patients at The Oncology Institute “Prof. Dr. Ion Chiricuță,” Cluj-Napoca, Romania.Methods: This non-randomized, observational, retrospective study included cancer patients who had a PCS implanted at The Oncology Institute “Prof. Dr. Ion Chiricuță,” Cluj-Napoca, between 1 January 2024 and 31 December 2024 and were enrolled in a follow-up protocol to monitor and manage PCS-related complications. This study evaluated the incidence of complications, their association with predefined prognostic factors, and their management.Results: In the study cohort (n= 124 patients), complications related to the PCS were observed in 20% of the patients, with a mean interval to complication onset of 47 days. Early-onset complications were observed in 40% of patients, while the remaining 60% developed late-onset complications. PCS infection was the most common complication (10 patients), followed by wound dehiscence and thrombosis (6 patients each). Bleeding, extravasation, catheter migration, port malfunction, and torsion were each documented in a single patient. No prognostic factors were significantly associated with early or late PCS complications, with thrombosis approaching significance (p= 0.051).Conclusions: PCSs are generally safe in oncology patients; infections and thrombosis predominate as PCS-related complications, but rarely require removal, and standardized care enables long-term use, improving patient quality of life.
背景：随着癌症发病率和死亡率的上升，中心静脉导管（CVCs）的使用日益增多，包括经外周静脉置入的中心静脉导管（PICCs）和输液港系统（PCSs），这些装置在治疗实施中发挥着重要作用。然而，CVCs常伴随机械性、感染性和血栓性并发症。本研究旨在评估罗马尼亚克卢日-纳波卡“Ion Chiricuță”教授肿瘤研究所肿瘤患者中PCS相关并发症及其处理情况。 方法：这项非随机、观察性、回顾性研究纳入了2024年1月1日至2024年12月31日期间在“Ion Chiricuță”教授肿瘤研究所植入PCS的癌症患者，并纳入随访方案以监测和管理PCS相关并发症。研究评估了并发症的发生率、其与预设预后因素的相关性以及处理措施。 结果：在研究队列（n=124例患者）中，20%的患者出现了PCS相关并发症，平均并发症发生时间为47天。40%的患者出现早发性并发症，其余60%出现迟发性并发症。PCS感染是最常见的并发症（10例），其次是伤口裂开和血栓形成（各6例）。出血、外渗、导管移位、输液港功能障碍和扭转各在1例患者中出现。未发现任何预后因素与PCS早发或迟发并发症显著相关，其中血栓形成接近显著性（p=0.051）。 结论：PCS在肿瘤患者中总体安全性良好；感染和血栓形成是主要的PCS相关并发症，但很少需要移除装置，标准化护理能够实现长期使用，从而改善患者生活质量。
Complications of Port-a-Cath Systems: An Institutional Study on Romanian Oncological Patients
肿瘤(癌症)患者之家